A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Phase of Trial: Phase I/II
Latest Information Update: 21 Sep 2018
At a glance
- Drugs BIVV 001 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms EXTEN-A
- Sponsors Bioverativ
- 13 Sep 2018 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
- 13 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
- 29 May 2018 According to a Bioverativ media release, company has announced preliminary clinical data from this trial